CN114949094A - 一种治疗跌打损伤及癌症疼痛的药物及其制备方法 - Google Patents
一种治疗跌打损伤及癌症疼痛的药物及其制备方法 Download PDFInfo
- Publication number
- CN114949094A CN114949094A CN202210742872.XA CN202210742872A CN114949094A CN 114949094 A CN114949094 A CN 114949094A CN 202210742872 A CN202210742872 A CN 202210742872A CN 114949094 A CN114949094 A CN 114949094A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- blood
- pain
- borneol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 229940079593 drug Drugs 0.000 title claims abstract description 22
- 208000014674 injury Diseases 0.000 title claims abstract description 15
- 230000008736 traumatic injury Effects 0.000 title claims abstract description 14
- 206010058019 Cancer Pain Diseases 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 17
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940116229 borneol Drugs 0.000 claims abstract description 17
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 17
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 16
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 16
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 16
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 16
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 16
- 241001043298 Croton draco Species 0.000 claims abstract description 16
- 239000004863 Frankincense Substances 0.000 claims abstract description 16
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 16
- 229910052956 cinnabar Inorganic materials 0.000 claims abstract description 16
- 239000009136 dragon's blood Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 229940098465 tincture Drugs 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 33
- 230000036407 pain Effects 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 18
- 230000000857 drug effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 230000017423 tissue regeneration Effects 0.000 abstract description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 8
- 229940035676 analgesics Drugs 0.000 description 8
- 239000000730 antalgic agent Substances 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003359 percent control normalization Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000010446 mirabilite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000018962 mouth sore Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗跌打损伤及癌症疼痛的药物及其制备方法。它是以血竭、冰片、乳香、没药、朱砂为原料制得,该药物可以制成临床使用的多种药剂,本发明组方中诸药配伍合理,协同治疗,其中乳香、没药为主药,行气活血,主攻对人体的止痛之功;血竭为佐药,化瘀生肌敛疮,冰片作为臣药,引导药效通达至人体各部,可对人体不同经络、不同部位的疼痛进行治疗、缓解,临床试验证明,本发明药物效果明显,并且无毒副作用,临床应用安全可靠。
Description
技术领域
本发明涉及到一种止痛的药物,特别涉及到一种以中草药为原料制备的治疗跌打损伤及癌症疼痛的药物,本发明还涉及该药物的制备方法。
背景技术
止痛药是医学领域的常见药物,止痛药又称镇痛药,指能部分或完全缓解疼痛的药物。目前常用止痛药一般有以下几类:1、非甾体性抗炎镇痛药:临床最常见,如阿司匹林、布洛芬、消炎痛等;2、中枢性止痛药:典型代表是曲马多缓释片;3、麻醉性止痛药:最常见的吗啡、杜冷丁、羟考酮等,均为阿片类代表性麻醉性止痛药;4、神经痛止痛药:可能了解比较少,主要常见的药有卡马西平、加巴喷丁和普瑞巴林等。
在当前市售的诸多的各种止疼药物,存在以下不足:一是适应症较为单一,尚无一种止疼痛的药剂可全面的用于各种疼痛,尤其针对癌症的止疼剂;二是有效率不理想,副作用较大。这也是该领域亟待改善的技术问题。
发明内容
本发明旨在提供一种治疗效果好、成本低、副作用小的一种治疗跌打损伤及癌症疼痛的药物及其制备方法,提供该药物的制备方法是本发明的另一发明目的。
本发明的药物是由下述质量配比的原料制成:
血竭25-40份、冰片50-70份、乳香25-40份、没药25-40份、朱砂15-25份。
本发明药物各组份进一步的质量配比是:
血竭30份、冰片60份、乳香30份、没药30份、朱砂20份。
本发明药物可以制成任何一种药剂学上所说的剂型,这里以酊剂为优选剂型。
本发明药物的具体制备方法如下:
将以下质量配比的药物:血竭25-40g、冰片50-70g、乳香25-40g、没药25-40g、朱砂15-25g,制备成粉末,加入40%-78%乙醇400-600g搅拌浸泡120小时以上,制成酊剂。
本发明药物中:
血竭,具有活血定痛,化瘀止血,生肌敛疮的功效;常用于跌打损伤,心腹瘀痛,外伤出血,疮疡不敛,疮面久不愈合等。
乳香,辛、苦,温;归心、肝、脾经;活血舒筋,行气止疼,瘀阻气滞,筋络不和。用于胸痹心痛,胃脘疼痛,痛经经闭,产后瘀阻,症瘕腹痛,风湿痹痛,筋脉拘挛,跌打损伤,痈肿疮疡。
没药,具有行气活血,消肿止疼,散瘀生肌之功效;常用于胸痹心痛,胃脘疼痛,痛经经闭,产后瘀阻,癥瘕腹痛,风湿痹痛,跌打损伤,痈肿疮疡等病症的治疗。
冰片,味辛、苦,微寒;归心、脾,肺经;芳香开窍,散热止疼。主治热病高热神昏,中风痰厥惊痫,暑湿蒙蔽清窍,喉痹耳聋,口疮齿肿,疮痈疳痔,目赤肿痛,翳膜遮睛。凡痰火郁闭,喉痹音哑,或火热壅滞,口疮齿肿者,冰片可与朱砂、硼砂、玄明粉配伍吹搽患处,以散火解毒。
朱砂,甘,微寒;归心经,清心镇惊,安神,明目,解毒。用于心悸易惊,失眠多梦,癫痫发狂,小儿惊风,视物昏花,口疮,喉痹,疮疡肿毒,外用能抑杀皮肤细菌和寄生虫。
方中诸药合理配伍,科学施治,其中乳香、没药为主药,行气活血,主攻对人体的止痛之功;血竭为佐药,化瘀生肌敛疮,冰片作为臣药,引导药效通达至人体各部,可对人体不同经络、不同部位的疼痛进行治疗、缓解。方中各组分协同配合,形成一个有效的治疗系统。现有技术中,经典药方存在乳香、没药的组合,但其止疼效果远达不到医疗需要,一方面,现有止痛类中药,内服药物居多,药量小,见效慢,尤其是是用于癌症患者疼痛症状的止痛过程,完全达不到预期医疗效果,因此,目前癌症重症患者常采用杜冷丁等药物,而与杜冷丁等药物相比,本发明药物的优势,一是没有成瘾性,二是取药便利,杜冷丁药物都是限量供给,每次取药需采用医院处方,现在民间广大癌症患者很多不住院治疗,无法及时持有处方并获取足量的杜冷丁,无法满足止痛要求;三,本药物采用特殊的外敷治疗方法,得到了显著的止痛疗效;传统止痛类中药尚很少采用本发明药方的剂型;四,本药物治疗时采用外用方式,属于针对性强的定点靶向治疗,对人体肝肾负担小,无毒副作用;五,每次用药,药效持续时间较长,一般为2-4小时,取得了较好的治疗效果,并产生不亚于杜冷丁的去痛效果;六,药理不同,杜冷丁药物原理是单纯的麻醉神经,而本药物更加全面,活血散瘀,对癌症肿瘤有消散、治疗作用,兼具了去痛作用。
治疗时,将该药物外敷的方式进行治疗,可将本药物涂抹于患者疼痛部位的体表处即可;也可以采用一些外用药的辅助载体,使得本药物可以缓慢持续在体表释放。
为进一步证明本发明药物的疗效,提供以下技术内容:
诊断方法:
针对不同种类的疼痛,采用一般检查、神经功能检查、神经功能检查、感觉功能检查、各种反射的检查、影像学诊断等手段进行分类、全面诊断。
临床试验一:
以肝癌患者为统计对象,治疗组采用本发明技术方案所述药物,对照组采用奥施康定、艾瑞昔布两种药物。
患者人数 | 有效 | 有效率 | |
治疗组 | 40 | 39例 | 97.5% |
对照组 | 40 | 34例 | 82.5% |
临床试验二:
以跌打损伤患者为统计对象,治疗组采用本发明技术方案所述药物,对照组采用尼美舒利胶囊。
患者人数 | 有效 | 有效率 | |
治疗组 | 100 | 98例 | 98% |
对照组 | 100 | 86例 | 86% |
临床试验三:
以腰部疼痛患者为统计对象,治疗组采用本发明技术方案所述药物,对照组采用市售常规药物。
患者人数 | 有效 | 有效率 | |
治疗组 | 20 | 19例 | 95% |
对照组 | 20 | 11例 | 55% |
临床试验四:
以6例电光性眼炎患者为统计对象,治疗组采用本发明技术方案所述药物,治疗时患者闭上双眼,采用本药物涂抹至患者眼睑及太阳穴处,10分钟后有效率100%,疼痛感显著减小,有的疼痛感完全消失。
临床试验五:
以12例带状疱疹后遗症神经痛患者为统计对象,在患者痛处用药5-6分钟,疼痛感缓解或者消失,有效率100%,经临床统计及分析,本发明药物对上述症状出了止痛作用,还有一定的治愈作用,神经痛症状的出现频率降低,出现总时间缩短;
临床试验六:
以19例痛风患者为统计对象,在患者痛处用药4-7分钟,疼痛缓解或者消失,有效率100%。
综合上述临床统计数据,结合其他疼痛患者试验及少量非典型性病例,可以得出,本发明所述药物可适用于多种常见疼痛症状,尤其擅长于各种跌打损伤,骨折,急性腰部损伤等未见皮破血流的疼痛治疗,用于各种癌症的疼痛治疗,是强麻止疼药物杜冷丁等的替代药物。且使用方法简单,安全可靠,疗效确切。
具体实施方式
下面结合实施例对本发明作进一步详细说明,但不构成对本发明的任何限制。
实施例1:
按照下述重量准备原材料:
血竭30g、冰片60g、乳香30g、没药25g、朱砂20g,
将上述药物制成粉末,加入浓度为50%的乙醇550g,搅拌静置120小时,过滤,即得成品。
实施例2:
按照下述重量准备原材料:
血竭40g、冰片55g、乳香25g、没药30g、朱砂15g,
将上述药物制成流浸膏,加入浓度为40%的乙醇500g,搅拌静置200小时,过滤,即得成品。
实施例3:
按照下述重量准备原材料:
血竭25g、冰片70g、乳香40g、没药40g、朱砂25g;
将上述药物制成粉末,加入浓度为60%的乙醇460g,搅拌静置100小时,过滤,即得成品。
实施例4:
按照下述重量准备原材料:
血竭25g、冰片70g、乳香40g、没药40g、朱砂25g;
将上述药物制成粉末,加入浓度为45%的乙醇540g,搅拌静置130小时,过滤,即得成品。
实施例5:
按照下述重量准备原材料:
血竭25g、冰片70g、乳香40g、没药40g、朱砂25g;
将上述药物制成粉末,加入浓度为55%的乙醇510g,搅拌静置150小时,过滤,即得成品。
实施例6:
按照下述重量准备原材料:
血竭25g、冰片70g、乳香40g、没药40g、朱砂25g;
将上述药物制成粉末,加入浓度为78%的乙醇400g,搅拌静置110小时,过滤,即得成品。
以上仅以部分实施例对本发明进行说明,并不构成对本发明的任何限制,凡在本发明的精神和原则内做出的任何修改、改进及等同替换等,均应包含在本发明的保护范围之内。
Claims (4)
1.一种治疗跌打损伤及癌症疼痛的药物,其特征在于:是由以下质量配比的原料制成:
血竭25-40份、冰片50-70份、乳香25-40份、没药25-40份、朱砂15-25份。
2.根据权利要求1所述的治疗跌打损伤及癌症疼痛的药物,其特征在于:各组份进一步的质量配比是:
血竭30份、冰片60份、乳香30份、没药30份、朱砂20份。
3.根据权利要求1所述的治疗跌打损伤及癌症疼痛的药物,其特征在于:本发明药物的剂型采用酊剂。
4.根据权利要求1所述的治疗跌打损伤及癌症疼痛的药物,其特征在于:本发明药物的制备方法如下:
将以下质量配比称取原料药:血竭25-40g、冰片50-70g、乳香25-40g、没药25-40g、朱砂15-25g,将上述原料药制备成粉末,加入40%-78%乙醇400-600g,搅拌,浸泡120小时以上,制成酊剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210742872.XA CN114949094A (zh) | 2022-06-28 | 2022-06-28 | 一种治疗跌打损伤及癌症疼痛的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210742872.XA CN114949094A (zh) | 2022-06-28 | 2022-06-28 | 一种治疗跌打损伤及癌症疼痛的药物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114949094A true CN114949094A (zh) | 2022-08-30 |
Family
ID=82965902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210742872.XA Pending CN114949094A (zh) | 2022-06-28 | 2022-06-28 | 一种治疗跌打损伤及癌症疼痛的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114949094A (zh) |
-
2022
- 2022-06-28 CN CN202210742872.XA patent/CN114949094A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101461921B (zh) | 一种治疗妇科疾病的药物组合物 | |
CN1238050C (zh) | 一种治疗痹症的中药膏剂及其制备方法 | |
CN114949094A (zh) | 一种治疗跌打损伤及癌症疼痛的药物及其制备方法 | |
CN109700856A (zh) | 一种具有活血通络、舒筋止痛的中药外用方剂 | |
CN1076628A (zh) | 愈尔膏 | |
CN102319330B (zh) | 一种治疗骨质增生的中药巴布膏及其制备方法 | |
CN102078516B (zh) | 一种治疗骨伤的中药 | |
CN106728050B (zh) | 一种治疗麻痹性肠梗阻的中药脐贴及制备方法 | |
CN110201087A (zh) | 一种治疗带状疱疹的外用药 | |
CN100408048C (zh) | 一种治疗风湿、类风湿、肩周炎的胶囊及其制备方法 | |
CN108403740A (zh) | 八宝丹及其制剂在制备治疗血精症的药物中的应用 | |
CN104623432A (zh) | 一种消除治疗肿瘤的中药组合物 | |
CN1054533C (zh) | 消炎止痛胶囊 | |
RU2076731C1 (ru) | Средство и способ повышения неспецифической резистентности организма при заболеваниях внутренних органов | |
CN115429869B (zh) | 一种治疗寒湿痹阻型腰痛的中药物组合物及其制备方法 | |
CN103272195A (zh) | 一种治疗疼痛的中药膏 | |
CN103157011B (zh) | 一种促进骨折愈合的中药组合物 | |
CN110420305B (zh) | 一种用于治疗慢性筋伤的中药组合物及其制备方法 | |
CN105853635A (zh) | 一种治疗冠心病心绞痛的药物组合物 | |
CN101297937B (zh) | 一种治疗颈椎病的中成药制剂及其制备方法 | |
CN1233373C (zh) | 治疗脊椎疾病的中药组合物 | |
CN1231920A (zh) | 一种治疗淋巴结核药物的配方及其制作工艺 | |
CN105232642A (zh) | 一种促进骨折愈合的中药组合物 | |
CN112220835A (zh) | 一种治疗风湿病症的外用擦剂 | |
CN116942740A (zh) | 一种治疗腰椎间盘突出症的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220830 |